Tamura Shigeyuki, Miki Hirofumi, Okada Kaoru, Yoshimura Mio, Uji Kumiko, Yoshida Atsuko, Yoshioka Yasumasa, Suzuki Rei, Nakahira Shin, Egawa Chiyomi, Nakata Ken, Okamura Shu, Sugimoto Keishi, Takatsuka Yuichi
Department of Surgery, Kansai Rosai Hospital.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2000-2.
Laparoscopy (st-lap) was performed for type 4 advanced gastric cancer cases, and chemotherapy was performed for P1 or CY1[ P(+)] cases. We present the results here.
The subjects were type 4 advanced gastric cancer cases from October 2002 to December 2007 who underwent st-lap, as well as 7 P0 and CY0 [P(-)] cases (the operative group), and 18 P(+) cases which underwent chemotherapy (the chemotherapy group). The administration of S-1 (80 mg/m2: days 1-14)+PTX (120 mg/m2: day 1) every 3 weeks was the basic regimen of chemotherapy.
After 5- course of chemotherapy, st-lap was performed in 11-PR case(61%) and 4-SD case, in which clinical symptoms had improved. An operation was performed for 11-P(-) case. Overall, there was 8-P(-) case(44%). The 1-and 3-year survival rates in the chemotherapy group in the 11 cases for which an operation was performed were 82 and 36%, respectively, and the 7 non-operative cases were 57 and 14%, respectively. Although there were no significant differences, the outcome was more favorable in the operative group. The 1-and 2-year survival rates in the operative and chemotherapy groups were 72, 39, 51 and 34%, respectively, and there was no significant difference.
It was suggested that in cases of type 4 advanced gastric cancer, chemotherapy was necessary not only in P(+) but also in P(-) cases. Further investigation regarding the necessity of resection and choice of therapeutic regimen is required.
对4型进展期胃癌病例进行了腹腔镜手术(st-lap),对P1或CY1[P(+)]病例进行了化疗。我们在此展示结果。
研究对象为2002年10月至2007年12月接受st-lap手术的4型进展期胃癌病例,以及7例P0和CY0[P(-)]病例(手术组),和18例接受化疗的P(+)病例(化疗组)。每3周给予S-1(80mg/m²:第1 - 14天)+PTX(120mg/m²:第1天)是化疗的基本方案。
化疗5个疗程后,11例PR病例(61%)和4例SD病例接受了st-lap手术,其临床症状有所改善。对11例P(-)病例进行了手术。总体而言,有8例P(-)病例(44%)。在接受手术的11例化疗组病例中,1年和3年生存率分别为82%和36%,7例未手术病例分别为57%和14%。虽然差异无统计学意义,但手术组的结果更优。手术组和化疗组的1年和2年生存率分别为72%、39%、51%和34%,差异无统计学意义。
提示在4型进展期胃癌病例中,不仅P(+)病例,P(-)病例也需要化疗。关于切除的必要性和治疗方案的选择需要进一步研究。